HCA Healthcare, a leading provider of healthcare services, has announced a successful integration at the Sarah Cannon Cancer Institute (SCCI), transitioning over 75% of CAR T-cell therapy patients to outpatient monitoring. This innovative approach has saved more than 1,200 hospital bed days for the initial 100 patients, with approximately 20% avoiding hospitalization entirely.
Implemented across four Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN) sites, the program utilizes advanced technology for remote patient monitoring, empowering outpatient clinical teams to manage post-treatment care effectively. Dr. Navneet Majhail, physician-in-chief of blood cancers at Sarah Cannon Transplant & Cellular Therapy Network, emphasizes the benefits of outpatient care for patients undergoing complex therapies like CAR T-cell treatments.
CAR T-cell therapy, an immunotherapy aimed at combating cancer by programming the patient’s immune system, demands intensive monitoring post-infusion. Historically, patients required extended inpatient stays for up to two weeks after treatment. However, through collaboration with Best Buy Health, SCTCTN initiated a transition to home monitoring using the Current Health platform, tailored for CAR T-cell therapy patients.
The success of this initiative will be presented at the upcoming Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR. HCA Healthcare plans to expand this model to additional SCTCTN sites, aiming to enhance patient care experiences nationwide.
HCA Healthcare, with its vast research network and commitment to innovation, continues to lead in delivering patient-centered care and advancing medical science. With millions of patient encounters annually, HCA Healthcare remains dedicated to improving healthcare outcomes and saving lives.
